{"schema_version":"secwatch.filing_event.v1","accession":"0001806952-25-000007","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.060596+00:00","generated_at":"2026-05-17T14:49:29.052768+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lyell Immunopharma Q2 net loss narrows to $42.7M; raises $100M private placement; LYL314 shows 72% CR rate","bullets":["Net loss of $42.7M in Q2 2025 vs $45.8M YoY; non-GAAP net loss $37.8M.","Private placement up to $100M ($50M initial at $13.32/share); pro-forma cash $347M.","LYL314 Phase 1/2 data: 88% ORR, 72% CR in 3L+ LBCL; manageable safety; PiNACLE pivotal trial initiated.","R&D expenses $34.9M (-13% YoY); G&A expenses $9.8M (-20% YoY).","Phase 3 trial for 2L LBCL expected by early 2026; LYL314 granted RMAT and Fast Track designations."],"urls":{"canonical":"https://secwatch.observer/filing/0001806952-25-000007","json":"https://secwatch.observer/filing/0001806952-25-000007.json","markdown":"https://secwatch.observer/filing/0001806952-25-000007.md","text":"https://secwatch.observer/filing/0001806952-25-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000180695225000007/0001806952-25-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000180695225000007/lyel-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:49:29.052768+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}